Advertisement

Chinese Journal of Clinical Oncology

, Volume 1, Issue 1, pp 37–41 | Cite as

HBME-1, CD15 and p53 protein expression in thyroid carcinoma and their significance in diagnosis

  • Jianying Liu
  • Jingping Yang
  • Songlin Liao
Original Article
  • 13 Downloads

Abstract

Objective

To investigate the protein expression of HBME-1, CD15 and p53 in thyroid carcinoma and in bengin thyroid diseases and to evaluate their value in diagnosis of thyroid disease.

Methods

Sixty-one cases of thyroid carcinoma and 27 cases of different kinds of benign thyroid diseases were studied by immunohistochemical methods.

Resutls

All cases of differentiated thyroid carcinoma were positive for HBME-1, 35.7% positive for CD15 and only 14.3% positive for p53. Twenty-seven cases of benign thyroid lesions were absolutely negative for p53, 7.4% of which were CD15 positive and 25.9% of which were HBME-1 positive.

Conclusion

HBME-1 and CD15 may be helpful to assist differential diagnosis of thyroid carcinoma from benign thyroid diseases.

Keywords

thyroid carcinoma HBME-1 CD15 p53 immunohistochemistry diagnosis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Christopher D M Fletcher. Diagnostic histopathology of tumors, 2nd. Churchill Livingstone, 2000; 963.Google Scholar
  2. 2.
    Livolsi VA. Surgical pathology of the thyroid. WB Saunders company, 1990;131.Google Scholar
  3. 3.
    Scopa CD, Melachrinou M, Saradopoulou C, et al. The significance of the grooved nucleus in thyroid lesions. Mod Pathol, 1993; 6:691–694.PubMedGoogle Scholar
  4. 4.
    Miettinen M, Karkkainen P. Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumors. Preferential reactivity with malignant tumours. Virchows Arch, 1996;429:213–219.PubMedCrossRefGoogle Scholar
  5. 5.
    Pollina L, Pacini F, Fontanini G, et al. bcl-2, p53 and proliferating cell nuclear antigen expression is related to the degree of differentiation in thyroid carcinomas. Br J Cancer, 1996; 73:139–143.PubMedGoogle Scholar
  6. 6.
    Kilicarslan B, Pesterelli EH, Oren N, et al. Epithelial membrane antigen and S-100 protein expression in benign and malignant papillary thyroid neoplasma. Adv Clin Path, 2000; 4:155–158.PubMedGoogle Scholar
  7. 7.
    Mai KT, Landry DC, Thomas J, et al. Follicular adenoma with papillary architecture; a lesion mimicking papillary thyroid carcinoma. Histopathology, 2001;39:25–32.PubMedCrossRefGoogle Scholar
  8. 8.
    Cheung CC, Ezzat S, Freeman JL, et al. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol, 2001;14:338–342.PubMedCrossRefGoogle Scholar
  9. 9.
    Ordonez NG. The immunohistochemical diagnosis of malignant mesothelioma. Differention of mesothelioma and lung adenocarcinoma. Am J Surg Pathol, 1989;13:276–291.PubMedGoogle Scholar
  10. 10.
    Schroder S, Schwarz W, Rehpenning W, et al. Prognostic significance of Leu-M1 immunostaining in papillary carcinomas of the thyroid gland. Virchows Arch A Pathol Anat Histopathol, 1987; 411:435–439.PubMedCrossRefGoogle Scholar
  11. 11.
    Shahedian B, Shi Y, Zou M, et al. Thyroid carcinoma is characterized by genomic instability: evidence from p53 mutations. Mol Genet Metab, 2001; 72:155–163.PubMedCrossRefGoogle Scholar
  12. 12.
    Dobashi Y, Sakamoto A, Sugimura H, et al. Over expression of p53 as a possible prognostic factor in human thyroid carcinoma. Am J Surg Pathol, 1993;17:375–381.PubMedCrossRefGoogle Scholar

Copyright information

© Chinese Anti-Cancer Association and Springer 2003

Authors and Affiliations

  1. 1.Department of PathologyHealth Science Center of Peking UniversityBeijingChina

Personalised recommendations